News from titan pharmaceuticals, inc. A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Feb 02, 2022, 08:45 ET Titan Pharmaceuticals Announces Pricing of $5.5 Million Registered Direct and PIPE Offering Priced At-The-Market

Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") today announced that it has entered into a securities purchase agreement with a ...

Dec 21, 2021, 08:00 ET Titan Pharmaceuticals to Explore Strategic Alternatives

Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") today announced that it has commenced a process to explore and evaluate...

Nov 08, 2021, 16:15 ET Sustained Anti-Pruritic Effect Of Titan's TP-2021 Implant Reported Today At Neuroscience 2021

Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") announced that, in a presentation given today at the Society for Neuroscience...

Nov 05, 2021, 16:30 ET Titan Announces Upcoming TP-2021 Implant Data Presentation at Neuroscience 2021

Titan Pharmaceuticals, Inc. announced that data from continuing studies of its ProNeura®-based TP-2021 implant in an established animal model of...

Oct 25, 2021, 07:15 ET Titan Pharmaceuticals Receives Funding to Develop Combination HIV Therapeutic and Contraceptive Implant for Women in Developing Countries

Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") today announced that it has received funding from the Bill & Melinda Gates...

Oct 12, 2021, 08:00 ET Titan Pharmaceuticals and MUSC FRD Enter Into Research and Option License Agreement

Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") today announced that it has entered into a research and option license...

Jun 23, 2021, 13:01 ET Titan Announces Positive Results from the First Studies of TP-2021 Implant in an Established Animal Model of Chronic Pruritus

Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) today announced that the in vivo study of its human kappa-opioid receptor agonist ("TP-2021," formerly...

Mar 31, 2021, 16:30 ET Titan Pharmaceuticals Announces Filing Of 2020 Annual Report On Form 10-K

Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) announced today that it has filed its annual report on Form 10-K for the fiscal year ended December 31,...

Feb 01, 2021, 07:30 ET Positive Early Study Results Help Pave Wave for Titan Pharmaceuticals to Move Forward with its JT-09 ProNeura® Development Program

Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) today announced that studies of its kappa opioid agonist peptide, JT-09, has demonstrated high potency and ...

Jan 15, 2021, 09:15 ET Titan Pharmaceuticals Announces Pricing of $9.7 Million Registered Direct Offering

Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) today announced it has entered into a securities purchase agreement with certain accredited institutional...

Dec 16, 2020, 08:00 ET Titan Pharmaceuticals Regains Compliance with Nasdaq Listing Requirements

Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("the "Company") today announced that on December 15, 2020, it received a notification letter from The...

Nov 30, 2020, 12:50 ET Titan Pharmaceuticals Announces Reverse Stock Split

Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") today announced that its Board of Directors has approved a 1-for-30 reverse...

Nov 16, 2020, 08:45 ET Titan Pharmaceuticals Reports Third Quarter 2020 Financial Results

Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") today reported financial results for the third quarter ended September 30, 2020 ...

Nov 02, 2020, 08:00 ET Titan Pharmaceuticals Completes Debt Settlement With Molteni And Horizon & Acquisiton Of JT Pharma's Kappa Opioid Agonist Peptide, JT-09

Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) today announced the completion of its agreement to settle all of its debt obligations with Molteni & C. dei ...

Oct 28, 2020, 15:00 ET Titan Pharmaceuticals Announces Pricing of $8.0 Million Underwritten Public Offering

Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) today announced the pricing of an underwritten public offering of 80,000,000 units at a price of $0.10 per ...

Oct 28, 2020, 08:00 ET Titan Pharmaceuticals Enters Into Definitive Agreement To Acquire JT Pharma's Kappa Opioid Agonist Peptide, JT-09

Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) today announced that it has entered into a definitive asset purchase agreement (the "Agreement") with JT...

Oct 26, 2020, 06:30 ET Titan Pharmaceuticals Announces Debt Settlement Agreement with Molteni and Horizon

Titan Pharmaceuticals, Inc. (NASDAQ:TTNP), a company developing proprietary therapeutics for the treatment of select chronic diseases utilizing its...

Oct 15, 2020, 08:00 ET Titan Pharmaceuticals Provides a Strategic & Corporate Update

Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) ("Titan" or the "Company") today announced a strategic restructuring designed to position it for future...

Sep 24, 2020, 09:00 ET Titan Pharmaceuticals Announces Pricing of $2.7 Million Registered Direct Offering

Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) today announced it has entered into a share purchase agreement with certain accredited institutional...

Sep 18, 2020, 16:45 ET Titan Pharmaceuticals' Stockholders Approve Proposal To Amend Its Certificate Of Incorporation

Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") announced that, at today's special meeting, its stockholders approved the...

Sep 15, 2020, 08:30 ET Titan's Probuphine® Commercialization Partner, Molteni, Enters Into Exclusive European Distribution Agreement With Accord Healthcare

Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") today announced that its partner, Molteni Farmaceutici ("Molteni"), has entered ...

Sep 14, 2020, 08:30 ET Titan Pharmaceuticals Provides Update To Stockholders On Proposal To Amend Its Certificate Of Incorporation

Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") today provided an update on the upcoming special meeting of stockholders (the...

Aug 14, 2020, 08:45 ET Titan Pharmaceuticals Reports Second Quarter 2020 Financial Results

Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") today reported financial results for the second quarter ended June 30, 2020 and ...

Aug 10, 2020, 16:30 ET Titan Pharmaceuticals To Report Second Quarter 2020 Financial Results On August 14, 2020

Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) today announced that its second quarter 2020 financial results will be released on Friday, August 14, 2020....

Jul 08, 2020, 08:00 ET Titan Pharmaceuticals Urges Stockholders to Vote "FOR" Proposal to Amend Its Certificate of Incorporation

Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") today urged its stockholders to vote "FOR" an amendment to its certificate of...